Purpose of Review Mivacurium is a short-acting non-depolarizing neuromuscular-blocking agent (NMBA) which has recently been re-released onto the US market. This review provides a brief overview about the pharmacology of mivacurium and discusses its use in recent clinical practice. Recent Findings Mivacurium has been reported to be especially useful in the pediatric population, especially for shorter cases, and infusions can be used for longer cases without inducing tachyphylaxis. As it is rapidly metabolized by pseudocholinesterase (PChE), mivacurium does usually not require a specific reversal agent to offset its actions at the end of surgery. Especially for use in short cases, this makes it a potentially advantageous alternative to the use of other NMBA. However, deficiencies in PChE as well as old age and some drug interactions can be associated with prolonged neuromuscular blockade. The rapid administration of higher doses may provoke significant histamine release leading to hemodynamic compromise. Summary Despite other NMBA being available on the market and its side effects, mivacurium may still be a useful agent in short cases, particularly in the pediatric population. . . . . Keywords Mivacurium Neuromuscular-blocking agent Pseudocholinesterase deficiency Cardiovascular instability Drug interactions Introduction been re-released in the USA after previous discontinuation
Current Anesthesiology Reports – Springer Journals
Published: Mar 22, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera